MedTrace Logo

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

NCT03126812 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-05-29

No results posted yet for this study

Summary

This is a single arm feasibility study in patients with primary FIGO stage IV serous ovarian, peritoneal, or fallopian tube cancer to evaluate neo-adjuvant + adjuvant pembrolizumab for its capacity to induce and broaden T cell responses against tumor neo-antigens.

Conditions

Interventions

DRUG

Carboplatin

Carboplatin AUC=6

DRUG

Paclitaxel

paclitaxel 80 mg/m2

DRUG

Pembrolizumab

200 mg flat dose, starting cycle 2

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2023-06-01
Completion
2024-03-05

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03126812 on ClinicalTrials.gov